Meissner’s TepoFlex® Biocontainer Is Now Available for Freeze & Thaw Applications

Share this Article

Camarillo, CA, US. January 28th 2026 – Meissner expands the application of its TepoFlex® biocontainer platform into freeze and thaw operations, delivering the same industry-trusted quality and performance to this demanding workflow. 

The robust security of the TepoFlex® polyethylene biocontainer film platform has been well established with clients over its nearly two decades of implementation. Leveraging the TepoFlex® film platform’s strengths, these biocontainers are manufactured to provide outstanding reliability and integrity throughout the harsh freeze/thaw cycle—extending the platform’s value for drug substance and drug product storage, transport, and process integration.

The 2D TepoFlex® biocontainers are suitable for freezing applications down to -80 degrees C. These single-use freeze and thaw biocontainers are available in volumes of 50 mL, 250 mL, 500 mL, 1 L, 2 L, 5 L, and 10 L to meet specific process requirements. 

The biocontainer’s flexible single-use design can be easily integrated into existing freeze/thaw infrastructure.  The biocontainer is compatible with a variety of freezers, including conventional blast freezers and vertical plate freezers. This enables deployment across various stages of drug development and manufacturing without major capital investment.

The TepoFlex® biocontainer offers biopharmaceutical manufacturers seeking secure, flexible, single-use solutions capable of safeguarding sensitive products in freeze/thaw processing conditions a robust option.

 These freeze and thaw biocontainers are manufactured in ISO-certified cleanrooms with qualified componentry to ensure biocompatibility and support regulatory compliance. Meissner’s Applications Engineering Team offers consultation for the design and optimization of clients’ single-use systems, and can ensure assemblies are tailored to optimize application requirements.

Meissner offers a uniquely enjoyable customer experience. Drawing on four decades of expertise, we take the time to understand our client’s objectives and challenges so that we can partner for future success.

To discover why leading biopharmaceutical manufacturers trust TepoFlex® for their most essential freeze and thaw applications, visit Meissner’s website at https://www.meissner.com/tepoflex-freeze-thaw where technical resources are available for download.

Additionally, visiting https://www.meissner.com/applications/freeze-thaw/ provides an overview of all of Meissner’s single-use freeze and thaw platform offerings.    

About Meissner
Meissner manufactures advanced microfiltration products and therapeutic manufacturing systems for critical pharmaceutical and biopharmaceutical applications, such as sterilization of injectable drugs, and the development and manufacture of life-enhancing/life-saving drugs, therapeutics, biologics, and cell and gene therapies.

Meissner’s manufacturing campuses include a headquarters location in Camarillo, California, USA, a European manufacturing location in Castlebar, Ireland, and buildout of a $250 million facility in Athens, Georgia.

Meissner’s product portfolios are built upon a solid foundation of quality, operational excellence, and technical expertise for delivery of high-performance products that support clients’ critical applications. For more information about Meissner, please visit https://www.meissner.com.

ENDS
Press Release published by

Got News You'd Like To Share With The World?

Press Release Distribution Starts from £95

PR Fire is here to help you stand out!

Using our simple pay-as-you-go portal, just select your targeted industry, and our team will begin custom-building your distribution.
Buy Now